COST-EFFECTIVENESS ANALYSIS OF THE ONCOTYPE DX BREAST RECURRENCE SCORE® TEST FOR POSTMENOPAUSAL WOMEN WITH HR+/HER2-NODE-POSITIVE EARLY BREAST CANCER IN CANADA

被引：0
|
作者：
Berdunov, V [1 ]
Richardson, R. [2 ]
Millen, S. [3 ]
机构：
[1] PHMR Ltd, London, England
[2] Exact Sci, Dartmouth, NS, Canada
[3] Exact Sci, London, England
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE194
引用
收藏
页码：S371 / S371
页数：1
相关论文
共 50 条
  • [31] Oncotype DX score in hormone receptor-positive/HER2-positive breast cancer: A SEER analysis.
    Qasrawi, Ayman
    Myint, Zin
    Alnimer, Yanal Mufeed
    Romond, Edward H.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [32] Prognostic impact of HER2-low expression according to the oncotype Dx recurrence score in hormone receptor-positive early breast cancer
    Mutai, R.
    Barkan, T.
    Moore, A.
    Sarfaty, M.
    Stemmer, S.
    Shohat, T.
    Yerushlami, R.
    Goldvaser, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S424 - S424
  • [33] Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey
    Unal, Caglar
    Ozmen, Tolga
    Ordu, Cetin
    Pilanci, Kezban Nur
    Ilgun, Ahmet Serkan
    Gokmen, Erhan
    Almuradova, Elvina
    Ozdogan, Mustafa
    Guler, Niluefer
    Uras, Cihan
    Kara, Halil
    Demircan, Orhan
    Isik, Selver
    Alco, Gul
    Saip, Pinar
    Aydin, Esra
    Duymaz, Tomris
    Celebi, Filiz
    Yararbas, Kanay
    Soybir, Gursel
    Ozmen, Vahit
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [34] The correlation between Ki 67 and Oncotype Dx on HR+, HER2-early breast cancer management: Insights of molecular testing.
    Campoverde, Leticia
    Camacho, Felipe
    Sanchez, Adriana
    Lugo, Paulina
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [35] Comparison of the cost-effectiveness of upfront letrozole or anastrozole, or switched exemestane versus tamoxifen for early breast cancer in hormone receptor positive (HR+) postmenopausal women: the UK perspective
    Di Trapani, F.
    Karnon, J.
    Kaura, S.
    EJC SUPPLEMENTS, 2007, 5 (04): : 202 - 203
  • [36] Validation of the GenesWell BCT Score in Young Asian Women With HR+/HER2-Early Breast Cancer
    Kwon, Mi Jeong
    Ryu, Jai Min
    Cho, Soo Youn
    Nam, Seok Jin
    Kim, Seok Won
    Lee, Jeeyeon
    Lee, Soo Jung
    Park, Ji-Young
    Park, Ho Yong
    Hong, Sungjun
    Kim, Kyunga
    Han, Jinil
    Moon, Youngho
    Shin, Young Kee
    Lee, Jeong Eon
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [37] Postmenopausal Women with HR+/HER2-Early Breast Cancer, 1-3 Positive Nodes, and a Low Risk of Recurrence Can Safely Forego Chemotherapy
    不详
    ONCOLOGIST, 2021, 26 : S11 - S12
  • [38] Cost of recurrence among patients with HR+/HER2-metastatic breast cancer.
    Engel-Nitz, Nicole M.
    Becker, Laura
    Gerdes, Randall
    Hao, Yanni
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [39] Cost-effectiveness of abemaciclib plus endocrine therapy in high-risk HR+/HER2-early breast cancer in China
    Wei, Qiran
    Xu, Yuting
    Liu, Wei
    Guan, Xin
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
  • [40] Cost-effectiveness of abemaciclib plus endocrine therapy in high-risk HR+/HER2–early breast cancer in China
    Qiran Wei
    YuTing Xu
    Wei Liu
    Xin Guan
    Cost Effectiveness and Resource Allocation, 21
12345